These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2126697)

  • 1. In vitro activity of BAY v 3522, a new oral cephalosporin.
    Fass RJ
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1855-7. PubMed ID: 2126697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
    Doern GV; Tubert TA
    Diagn Microbiol Infect Dis; 1990; 13(4):349-52. PubMed ID: 2127558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
    Chin NX; Gu JW; Neu HC
    Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro studies with Bay V 3522, a new oral cephalosporin.
    Thomson KS; Sanders CC; Sanders WE
    Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibilities of common pediatric pathogens to LY163892.
    Shelton S; Nelson JD
    Antimicrob Agents Chemother; 1988 Feb; 32(2):268-70. PubMed ID: 3129989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
    Doern GV
    Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.
    Nash DR; Flanagan C; Steele LC; Wallace RJ
    Antimicrob Agents Chemother; 1991 Jan; 35(1):192-4. PubMed ID: 1901696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
    Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH
    J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
    Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
    Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
    Doern GV; Vautour R
    Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
    Neu HC; Saha G; Chin NX
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1795-800. PubMed ID: 2589845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of BMY 28100, a new oral cephalosporin.
    Steele J; Edwards B; Rissing J
    Eur J Clin Microbiol; 1987 Feb; 6(1):111-3. PubMed ID: 3494601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of BAY v 3522, a new cephalosporin for oral administration.
    Hodges TL; Eliopoulos GM; Klimm K; Moellering RC
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1849-54. PubMed ID: 2285305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of amoxicillin plus clavulanic acid against Haemophilus influenzae and Branhamella catarrhalis.
    Liljequist BO; Gezelius L
    Eur J Clin Microbiol; 1986 Dec; 5(6):615-21. PubMed ID: 3492374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.
    Yamada T; Yokota Y; Ikeda F; Mine Y; Kitada T
    Chemotherapy; 1992; 38(1):28-35. PubMed ID: 1618001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Antimicrob Agents Chemother; 1990 May; 34(5):813-8. PubMed ID: 2360820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.